Case Study: Bicycle Accident Nerve Damage Treated with Pregabalin and Gabapentin Under Pharmacy Lien

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | October 28, 2024 | 10 min read

A cyclist struck by a car door suffered ulnar nerve damage requiring specialized neuropathic pain medication. The pharmacy lien program managed a complex Pregabalin/Gabapentin protocol over 10 months, generating clinical documentation that proved the nerve injury was permanent and supported a significant settlement.

Case Study: Bicycle Accident Nerve Damage Treated with Pregabalin and Gabapentin Under Pharmacy Lien

Nerve damage from bicycle accidents presents unique challenges in personal injury cases. Unlike fractures that show up clearly on imaging, neuropathic pain is largely invisible — diagnosed through symptoms, nerve conduction studies, and medication response. When the treatment itself becomes the evidence, pharmacy documentation takes on outsized importance. This case study demonstrates how detailed medication management records proved the severity and permanence of a cyclist's nerve injury.

[!KEY] Derek, 27, suffered permanent ulnar nerve damage in a dooring collision and required 10 months of Gabapentin/Pregabalin therapy — a documented discontinuation challenge proved the neuropathy was real and supported a significant settlement.

Patient Profile

• Patient: Derek Simmons (name changed), 27-year-old male, software engineer
• Incident: Riding in a designated bike lane in Santa Monica when a parked car's driver opened their door directly into Derek's path ("dooring"). Derek struck the door at approximately 18 mph, was thrown from the bicycle, and landed on his left side.
• Injuries: Left ulnar nerve entrapment at the elbow (cubital tunnel syndrome, traumatic), left elbow fracture (radial head), left hip contusion, facial lacerations requiring 14 stitches
• Attorney: Samantha Liu (name changed), bicycle accident specialist at a boutique PI firm in West LA
• Insurance situation: The at-fault driver's auto policy covered the claim under liability; Derek had health insurance through his employer but it had a $4,500 deductible he had not yet met
• Treatment duration: 10 months of pharmacological management

The Problem: Invisible Injury, Visible Skepticism

The elbow fracture healed in 8 weeks. The facial lacerations healed in 3 weeks. But the ulnar nerve damage — which caused numbness, tingling, and burning pain from Derek's elbow to his ring and pinky fingers — was not resolving.

Derek's orthopedic hand specialist ordered a nerve conduction study at 3 months post-accident, which confirmed moderate ulnar neuropathy at the elbow. The nerve had been compressed and stretched during the impact. The prognosis: partial recovery expected, but some degree of permanent neuropathy was likely.

The treatment approach was pharmacological:

The Defense Strategy

The insurer's defense counsel hired a medical expert who examined Derek at 4 months post-accident. The expert's opinion: the nerve conduction study showed "borderline" abnormality, the ulnar neuropathy was likely pre-existing (Derek used a computer all day — "classic cubital tunnel risk factor"), and the medications were excessive for the documented findings.

This is a common defense tactic in nerve injury cases. Because neuropathic pain is subjective and nerve conduction studies have a range of normal variation, the defense argues that the injury is either pre-existing, exaggerated, or both. The response requires objective evidence that the medications are working — evidence that proves the injury is real.

The Solution: Pharmacy Lien with Detailed Neuropathic Pain Documentation

Samantha referred Derek to LienScripts at the start of month 2, when it became clear that the neuropathic pain was not resolving and a long-term medication regimen was likely.

The Gabapentin-Pregabalin Protocol

The clinical team at LienScripts monitored the neuropathic pain medication titration in detail:

That last row was critical. At month 10, the treating physician attempted to discontinue Gabapentin to see if Pregabalin alone was sufficient. Within two weeks, Derek's pain increased from 3/10 to 4/10, and the numbness in his ring finger worsened. Gabapentin was resumed.

This documented "discontinuation challenge" — attempting to remove a medication and seeing symptoms worsen — is powerful medical evidence. It objectively demonstrates that the medication is treating a real condition, not providing placebo benefit.

[!KEY] A documented discontinuation challenge — where a medication is removed and symptoms objectively worsen — is among the strongest refutations of a defense expert's "pre-existing condition" or "over-prescribed" argument, because it proves the neuropathic injury responds to the specific medication rather than resolving on its own.

The Lidocaine Patch Documentation

An often-overlooked detail: the Lidocaine 5% patches were tracked by usage frequency. In months 2-4, Derek used a patch every day. By month 7-8, he used them 3-4 times per week. By month 10, he used them 1-2 times per week. This declining utilization pattern — documented in the pharmacy records — supported the narrative that the elbow inflammation was resolving even though the underlying nerve damage persisted.

[!KEY] PRN medication utilization patterns — how often a patient actually fills or uses as-needed prescriptions — are often more credible to adjusters and mediators than pain scores, because they represent objective refill behavior rather than patient self-report.

The Results

Settlement Impact

Samantha's demand was $425,000, based on:

• Permanent neuropathic pain requiring ongoing medication (Pregabalin and Gabapentin)
• The documented Gabapentin discontinuation challenge proving medication necessity
• Declining Lidocaine patch utilization corroborating recovery trajectory
• Future medical costs for neuropathic pain management (ongoing Pregabalin required)
• Impact on Derek's career (a software engineer who experiences hand numbness and pain)

The defense expert's report — arguing pre-existing cubital tunnel and excessive medication — was directly contradicted by the pharmacy documentation. The expert could not explain why a supposedly pre-existing condition responded to a post-accident medication titration protocol, or why a discontinuation attempt at month 10 produced measurable symptom worsening.

The case settled favorably after a single mediation session. The mediator explicitly noted that the pharmacy documentation was the strongest evidence supporting permanency.

Key Takeaways

"The mediator explicitly noted that the pharmacy documentation was the strongest evidence supporting permanency."

For Attorneys Handling Nerve Injury Cases

1. Medication response IS evidence of injury. In neuropathic pain cases where imaging is ambiguous and nerve conduction studies are "borderline," the patient's documented response to neuropathic medications is one of the strongest forms of objective evidence. A detailed medication titration record showing dose-response correlation proves the injury is real.

2. Discontinuation challenges are game-changers. If your client's physician attempts to reduce or discontinue a medication and symptoms worsen, that documented trial is worth more than almost any other single piece of evidence. Encourage your pharmacy to track these events in detail.

[!TIP] Request a supervised discontinuation trial when your client may need long-term neuropathic medication — a documented symptom flare upon stopping is among the strongest objective evidence of permanency available in nerve injury cases.

3. Track utilization patterns for PRN medications. Medications used "as needed" (like Lidocaine patches or Sumatriptan) produce utilization data that reflects the patient's condition over time. A declining pattern supports recovery; stable high use supports permanency. Both are valuable — but only if tracked.

4. Future medical costs require current medication documentation. You cannot demand future neuropathic pain medication costs without proving that the patient currently needs (and will continue to need) those medications. A 10-month medication record with dose adjustments, trials, and discontinuation challenges builds this foundation.

For Prescribers

5. Document your dose adjustment rationale. When you increase Gabapentin from 300mg to 600mg, note why. When you add Pregabalin to Gabapentin, note why the combination is needed. These clinical decisions, documented in pharmacy records, become evidence that supports your patient's case.

6. Consider discontinuation trials when clinically appropriate. If a patient may need long-term medication, a supervised attempt to reduce or discontinue the medication (with documentation of the outcome) provides powerful evidence of ongoing medical necessity.

Related Resources

• Pregabalin for Nerve Damage After Car Accidents
• Gabapentin for Whiplash and Nerve Pain
• How Long Will I Need Medications After an Accident?
• Pharmacy Services for Personal Injury Clients: How It Works

This case study is a composite based on multiple real cases. Names, identifying details, and specific figures have been modified to protect privacy. Results vary by case.